XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Data (Tables)
 6 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Area
Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues. On December 29, 2017, the Company completed its acquisition of C.R. Bard, Inc. ("Bard"), which is further discussed in Note 9. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018 and as such, are not included in the financial results detailed below for the first quarter of the prior-year six-month period.
 
Three Months Ended March 31,
(Millions of dollars)
2019
 
2018
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions
$
484

 
$
446

 
$
929

 
$
504

 
$
454

 
$
958

Medication Management Solutions
497

 
118

 
615

 
461

 
120

 
581

Diabetes Care
137

 
133

 
270

 
131

 
136

 
267

Pharmaceutical Systems
93

 
273

 
366

 
82

 
284

 
366

Total segment revenues
$
1,211

 
$
969

 
$
2,180

 
$
1,178

 
$
994

 
$
2,172

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
171

 
$
195

 
$
366

 
$
181

 
$
200

 
$
381

Diagnostic Systems
180

 
209

 
389

 
201

 
209

 
410

Biosciences
120

 
177

 
297

 
116

 
191

 
307

Total segment revenues
$
470

 
$
582

 
$
1,052

 
$
498

 
$
600

 
$
1,098

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery
$
271

 
$
75

 
$
345

 
$
276

 
$
75

 
$
351

Peripheral Intervention
194

 
148

 
342

 
194

 
145

 
338

Urology and Critical Care
195

 
80

 
275

 
180

 
84

 
264

Total segment revenues
$
659

 
$
303

 
$
963

 
$
649

 
$
303

 
$
952

 
 
 
 
 
 
 
 
 
 
 
 
Total Company revenues
$
2,341

 
$
1,854

 
$
4,195

 
$
2,325

 
$
1,898

 
$
4,222

 
Six Months Ended March 31,
(Millions of dollars)
2019
 
2018
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions
$
1,004

 
$
883

 
$
1,887

 
$
874

 
$
826

 
$
1,700

Medication Management Solutions
1,003

 
236

 
1,239

 
932

 
237

 
1,168

Diabetes Care
282

 
261

 
544

 
277

 
267

 
544

Pharmaceutical Systems
161

 
485

 
646

 
136

 
475

 
612

Total segment revenues
$
2,450

 
$
1,865

 
$
4,316

 
$
2,218

 
$
1,806

 
$
4,024

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
371

 
$
387

 
$
758

 
$
366

 
$
391

 
$
756

Diagnostic Systems
355

 
416

 
771

 
367

 
423

 
791

Biosciences
228

 
350

 
579

 
224

 
372

 
596

Total segment revenues
$
954

 
$
1,153

 
$
2,108

 
$
957

 
$
1,186

 
$
2,143

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery
$
545

 
$
148

 
$
693

 
$
428

 
$
99

 
$
528

Peripheral Intervention
385

 
294

 
679

 
198

 
146

 
344

Urology and Critical Care
393

 
168

 
560

 
180

 
84

 
264

Total segment revenues
$
1,323

 
$
609

 
$
1,932

 
$
806

 
$
329

 
$
1,135

 
 
 
 
 
 
 
 
 
 
 
 
Total Company revenues
$
4,728

 
$
3,628

 
$
8,355

 
$
3,982

 
$
3,321

 
$
7,302
Financial Information for Company's Segments
Segment income for the three and six-month periods was as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
(Millions of dollars)
2019
 
2018
 
2019
 
2018
Income Before Income Taxes
 
 
 
 
 
 
 
Medical (a) (b)
$
599

 
$
588

 
$
1,265

 
$
1,211

Life Sciences
293

 
336

 
598

 
652

Interventional (b)
231

 
(154
)
 
441

 
(72
)
Total Segment Operating Income
1,123

 
770

 
2,303

 
1,791

Acquisitions and other restructurings
(101
)
 
(104
)
 
(191
)
 
(458
)
Net interest expense
(153
)
 
(181
)
 
(336
)
 
(295
)
Other unallocated items (c)
(866
)
 
(479
)
 
(1,058
)
 
(926
)
Income Before Income Taxes
$
3

 
$
6

 
$
718

 
$
111

(a)
The amounts in 2019 include $65 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.
(b)
The amounts in 2018 included expense of $53 million and $369 million for the Medical and Interventional segments, respectively, related to the recognition of a fair value step-up adjustment of $422 million related to Bard's inventory on the acquisition date.
(c)
Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts in 2019 include a pre-tax charge of $331 million related to certain product liability matters, which is further discussed in Note 5. In addition, the amount for the six months ended March 31, 2019 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 10.